Centessa, formed earlier this year through a ten-way merger involving multiple spinouts, has completed a listing in the US.

Centessa Pharmaceutical, a UK-based pharmaceutical conglomerate formed through a ten-way merger involving spinouts from various universities, went public in a $330m initial public offering on Friday.

The company issued 16.5 million American Depositary Shares, representing the same number of ordinary shares, priced at $20 each. The spinout now trades on the Nasdaq Global Select Market using the ticker symbol CNTA and its shares closed at $21.75 on the first day of trading.

Founded in October 2020 as a holding…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in